CSL Limited
45 Poplar Road Parkville
Victoria 3052 Australia

T +613 9389 1911
F +613 9389 1434
www.csl.com.au

CSL ASX Announcement

For immediate release

9 October 2015

CSL Names David Lamont as Chief Financial Officer

CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today named Mr. David Lamont, an accomplished global financial leader with a diverse commercial background, as its Chief Financial Officer (***CFO***), effective 2 January 2016. He will be based at CSL's headquarters in Parkville, Australia. As announced in August, CSL CFO Mr. Gordon Naylor is transitioning to the role of President of Seqirus, the new global business created from the integration of bioCSL and the newly acquired Novartis influenza vaccines business.

"David has a demonstrated track record of success as a global CFO and brings key leadership skills that will continue to drive the disciplined financial management that has been one of the hallmarks of CSL's sustained success," said CSL CEO & Managing Director Mr. Paul Perreault. "Throughout his 30-year financial career, David has earned a reputation as a commercially-driven business leader, an important attribute as we invest in the commercialisation of our science for better patient outcomes. I look forward to working with David and the rest of our management team in executing our established strategy and continuing to sustainably grow our global business."

Mr. Lamont, 50, has served as CFO for several leading multi-national public companies across a range of industries since 1999 – including MMG Limited, Oz Minerals Limited, PaperlinX Limited, BHP Billiton's energy & coal and carbon steel materials divisions, and Incitec Pivot Limited. He is currently CFO and an Executive Director at MMG since 2010. Mr. Lamont served in a number of progressive financial leadership roles in the chemicals and agriculture industries before his appointment as CFO at Incitec Pivot in 1999. He holds a Bachelor of Commerce degree from Deakin University in Australia. Mr. Lamont is a qualified Chartered Accountant and a member of the Institute of Chartered Accountants.

"This is an incredibly exciting time to be a part of CSL. I am thrilled to join a growing global company and a proven management team that is so focused on creating value for shareholders, patients, employees and the communities in which it operates," Mr. Lamont said. "I look forward to contributing to CSL's future growth and success in delivering on the promise of innovative biotherapies to treat patients around the world."

CSL is a global biopharmaceutical company that develops, manufactures and markets biotherapies to prevent and treat rare and serious human diseases. CSL owns major facilities in Australia, Germany, Switzerland, the United Kingdom, and the United States,

and employs over 14,000 people in more than 30 countries. CSL operates two subsidiary businesses, CSL Behring and Seqirus, which are underpinned by a significant Research and Development effort. For more information, please visit www.csl.com.au.

For further information, please contact:

Investors:
Mark Dehring
Head of Investor Relations
CSL Limited
Phone: +613 9389 3407
Email: mark.dehring@csl.com.au

Media:
Sharon McHale
Head of Public Affairs
CSL Limited
Mobile +61 409 978 314
Email: sharon.mchale@csl.com.au